**China A-Share Drug Stocks Surge; He Lifeng Holds Trade Talks with US in New York**
China's A-share markets rose at midday on September 20, 2025, with the Shanghai Composite up 0.55% to 3,933.37. The rally was led by innovative drug and biotech stocks. Concurrently, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic consultations, covering bilateral trade and AI. The PBOC conducted a 165 billion yuan 7-day reverse repo at 1.40%. The NMPA and Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
China A-Share Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
China's A-share markets rose across the board at midday on September 20, with the Shanghai Composite up 0.55% to 3,933.37 points, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The PBOC conducted a 165 billion yuan 7-day reverse repo at 1.40%. In policy news, China's Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic consultations, discussing trade and AI issues. The NMPA and General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biotech, chemical pharma, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided stock-specific commentary: Tianfeng Securities noted Chengdu Biotech's HAILO platform and RIPTAC projects; Southwest Securities highlighted Huiyu Pharma's 13 innovative drug pipeline including HY-0007; Pacific Securities cited Hongbo Medical's growth from patent expirations; and Southwest Securities noted CanSino's accelerated overseas clinical progress.
China A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
China's A-share markets rose across the board at midday on September 20, with the Shanghai Composite Index up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at a rate of 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng held economic and trade consultations with US Treasury Secretary Bessent and Trade Representative Greer in New York, covering bilateral trade, investment, and AI issues. The National Medical Products Administration and the General Administration of Customs announced a pilot program for electronic customs clearance of imported drugs at Beijing ports, effective immediately. Sector-wise, recombinant protein, CRO, biopharmaceuticals, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts from Tianfeng, Southwest, and Pacific Securities provided forecasts for stocks including Chengdu Firstar, Huiyu Pharmaceutical, Hongbo Medical, and CanSino Biologics, citing pipeline progress, patent expirations, and overseas clinical acceleration as catalysts.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
A-share indices rose across the board at midday on September 20, 2025, with the Shanghai Composite up 0.55% to 3,933.37, the Shenzhen Component up 0.57% to 13,718.23, and the ChiNext up 0.93% to 3,403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic consultations, covering bilateral trade and AI issues. The NMPA and General Administration of Customs announced a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, innovative drugs, CRO, biotech, and chemicals led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Xianzhi's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharmaceutical's HY-0007 dual fusion antibody in Phase I trials; Pacific Securities predicted rapid growth for Hongbo Medical's commercial production after patent expiry; and Southwest Securities said CanSino's overseas clinical acceleration could unlock long-term pipeline value.
Read sourceShow 17 older updatesHide older updates
China A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
A-share indices rose at midday on September 20, 2025, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on AI. The National Medical Products Administration and General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, innovative drugs, CRO, biotech, and chemicals led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Biostar's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharmaceutical's 13 innovative drug projects including HY-0007; Pacific Securities predicted rapid growth for Hongbo Medical after patent expiry; and Southwest Securities said CanSino's overseas clinical progress could accelerate value realization.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
Chinese A-share markets rose at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng held trade consultations with US Treasury Secretary Bessent and Trade Representative Greer in New York, discussing bilateral trade and AI. The NMPA and General Administration of Customs launched a pilot for electronic clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biotech, chemical pharma, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Xian's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharma's 13 innovative drug projects including HY-0007; Pacific Securities cited Hongbo Medical's commercial production growth after ticagrelor patent expiry; and Southwest Securities said CanSino's overseas clinical trials are accelerating, potentially unlocking long-term pipeline value.
Read sourceChina Stocks Rise on Drug Policy, Sino-US Trade Talks; Innovation Drugs Surge
Chinese A-share markets rose in morning trading on September 23, 2025, with the Shanghai Composite Index up 0.55% to 3,933.37, the Shenzhen Component Index up 0.57%, and the ChiNext Index up 0.93%. The rally was led by innovation drug and clinical CRO stocks. Key drivers included a policy announcement by the National Medical Products Administration and the General Administration of Customs to pilot electronic customs clearance for imported drugs at Beijing ports, aiming to improve efficiency. Additionally, Sino-US economic and trade consultations were held in New York on September 20, led by Chinese Vice Premier He Lifeng and US Treasury Secretary Bessent and Trade Representative Greer, covering bilateral trade and AI issues. The People's Bank of China conducted a 16.5 billion yuan 7-day reverse repo at 1.40%. Analyst reports from Tianfeng, Southwest, and Pacific Securities highlighted specific companies: Chengdu Firstar's HAILO platform, Huiyu Pharmaceutical's HY-0007 drug candidate, Hongbo Medical's commercial production growth, and CanSino's overseas clinical progress.
Read sourceChina A-Share Innovation Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
Chinese A-share markets saw broad gains at midday on September 20, 2025, with the Shanghai Composite Index rising 0.55% to 3,933.37 points, the Shenzhen Component Index up 0.57%, and the ChiNext Index gaining 0.93%. The People's Bank of China conducted a 165 billion yuan 7-day reverse repo operation at a 1.40% interest rate. On the policy front, China's Vice Premier He Lifeng held economic and trade consultations with U.S. Treasury Secretary Bessent and Trade Representative Greer in New York, focusing on bilateral trade and investment, including a dialogue on artificial intelligence. Separately, the National Medical Products Administration and the General Administration of Customs announced a pilot program for electronic customs clearance of imported pharmaceuticals at Beijing ports. Sector-wise, innovation drugs, CRO, biotech, and chemical pharmaceuticals led gains, while precious metals and white goods underperformed. Analysts from Tianfeng Securities highlighted Chengdu Lead's HAILO platform and RIPTAC pipeline progress. Southwest Securities noted that Huiyu Pharmaceutical has 13 innovative drug projects in development, including HY-0007 for advanced solid tumors. Pacific Securities pointed to rapid growth in commercial production for Hongbo Medical following the expiration of ticagrelor patent extensions. Southwest Securities also said CanSino's overseas clinical trials are accelerating, potentially unlocking long-term value.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
Chinese A-share indices rose at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In policy news, China and the US held economic and trade consultations in New York, led by Vice Premier He Lifeng, Treasury Secretary Bessent, and Trade Representative Greer, covering bilateral trade and AI issues. Separately, the National Medical Products Administration and the General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, innovative drugs, CRO, biotech, and chemicals led gains, while precious metals and white goods lagged. Analyst reports highlighted: Chengdu Xian's HAILO platform and RIPTAC pipeline; Huiyu Pharma's HY-0007 bispecific fusion protein in Phase I/II trials for solid tumors; Hongbo Medical's commercialization growth after ticagrelor patent expiry; and CanSino's accelerated overseas clinical progress.
Read sourceChina A-Share Innovation Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
A-share indices rose at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng held economic consultations with US Treasury Secretary Bessent and Trade Representative Greer in New York, discussing bilateral trade and AI issues. The National Medical Products Administration and General Administration of Customs announced a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant protein, CRO, biotech, chemical pharma, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Xianzhi's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharmaceutical's 13 innovative drug projects including HY-0007; Pacific Securities predicted rapid growth for Hongbo Medical's commercial production after patent expiry; and Southwest Securities said CanSino's overseas clinical acceleration could unlock mid-to-long-term pipeline value.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
Chinese A-share markets rose at midday on September 20, 2025, with the Shanghai Composite Index gaining 0.55% to 3933.37 points, driven by a surge in innovative drug and biotech stocks. The Shenzhen Component Index rose 0.57%, the ChiNext Index added 0.93%, and the BeiBei 50 Index jumped 1.60%. The People's Bank of China conducted a 165 billion yuan 7-day reverse repo at 1.40% interest rate. On the policy front, China and the US held trade consultations in New York, led by Vice Premier He Lifeng and US Treasury Secretary Bessent and Trade Representative Greer, covering bilateral trade and AI issues. Separately, China's drug regulator and customs launched a pilot for electronic clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biotech, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts from Tianfeng, Southwest, and Pacific Securities provided positive outlooks for specific companies: Chengdu Firstar's HAILO platform, Huiyu Pharmaceutical's HY-0007 dual-antibody fusion protein, Hongbo Medical's generic drug export growth, and CanSino's overseas clinical progress.
Read sourceChina A-Share Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
Chinese A-share markets rose at midday on September 20, with the Shanghai Composite Index up 0.55% to 3933.37, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In trade news, Chinese Vice Premier He Lifeng met with U.S. Treasury Secretary Bessent and Trade Representative Greer in New York for constructive talks on bilateral economic issues and AI. The National Medical Products Administration and the General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant protein, CRO, biotech, chemical pharma, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Biostar's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharmaceutical's 13 innovative drug projects and its HY-0007 bispecific fusion protein in Phase I/II trials; Pacific Securities predicted rapid growth for Hongbo Medical's commercial production after the ticagrelor patent expiry; and Southwest Securities said CanSino's overseas clinical acceleration could unlock mid-to-long-term pipeline value.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
China's A-share markets rose across the board at midday on September 20, with the Shanghai Composite Index up 0.55% to 3,933.37, the Shenzhen Component up 0.57% to 13,718.23, and the ChiNext Index up 0.93% to 3,403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at a 1.40% rate. On the policy front, China and the US held economic and trade consultations in New York led by Vice Premier He Lifeng, Treasury Secretary Bessent, and Trade Representative Greer, covering bilateral trade, investment, and AI issues. Separately, the National Medical Products Administration and the General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biologics, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu First's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharma's 13 innovative drug projects including HY-0007 in Phase I trials; Pacific Securities predicted rapid growth for Hongbo Medical's commercial production after ticagrelor patent expiry; and Southwest Securities said CanSino's overseas clinical acceleration could unlock mid-to-long-term pipeline value.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
China's A-share markets rose across the board at midday on September 20, with the Shanghai Composite Index up 0.55% to 3,933.37, the Shenzhen Component Index up 0.57% to 13,718.23, and the ChiNext Index up 0.93% to 3,403.97. The People's Bank of China conducted 165 billion yuan in 7-day reverse repos at an interest rate of 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng held trade consultations with U.S. Treasury Secretary Bessent and Trade Representative Greer in New York, discussing bilateral trade and investment as well as artificial intelligence. The National Medical Products Administration and the General Administration of Customs announced a pilot program for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, innovative drugs, CRO, biotech, and chemicals led gains, while precious metals and white goods lagged. Analysts from Tianfeng Securities, Southwest Securities, and Pacific Securities provided positive outlooks on specific companies: Chengdu Xianzheng's HAILO platform, Huiyu Pharmaceutical's HY-0007 dual-antibody fusion protein, Hongbo Medical's commercialization ramp, and CanSino's overseas clinical progress.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
Chinese A-share markets rose across the board at midday on September 20, 2025, with the Shanghai Composite Index up 0.55% to 3,933.37, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The People's Bank of China conducted a 165 billion yuan 7-day reverse repo at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with U.S. Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on artificial intelligence. The National Medical Products Administration and the General Administration of Customs launched a pilot program for electronic clearance of imported drugs at Beijing ports. Sector-wise, innovative drug-related stocks such as recombinant proteins, CRO, biopharmaceuticals, and chemical drugs led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Biotech's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharmaceutical's 13 innovative drug projects including HY-0007; Pacific Securities predicted rapid growth for Hongbo Medical's commercial production after patent expiry; and Southwest Securities said CanSino's overseas clinical trials are accelerating, potentially unlocking long-term pipeline value.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
A-share indices rose at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on AI. The National Medical Products Administration and the General Administration of Customs announced a pilot program for electronic customs clearance of imported drugs at Beijing ports, effective immediately. Sector-wise, recombinant protein, CRO, biopharmaceuticals, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts from Tianfeng, Southwest, and Pacific Securities provided forecasts for specific stocks: Chengdu Firstar's HAILO platform and RIPTAC projects; Huiyu Pharmaceutical's HY-0007 dual antibody fusion protein in Phase I/II trials; Hongbo Medical's commercialization growth after patent expiry; and CanSino's accelerated overseas clinical trials.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
Chinese A-share indices rose at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on AI. The National Medical Products Administration and the General Administration of Customs announced a pilot program for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biopharmaceuticals, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Xian's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharma's 13 innovative drug projects and HY-0007 trial; Pacific Securities cited Hongbo Medical's commercialization growth after ticagrelor patent expiry; and Southwest Securities pointed to CanSino's accelerating overseas clinical trials.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
A-share indices rose at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In trade news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for constructive talks on bilateral economic issues and AI. The NMPA and General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biotech, chemical pharma, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Xian's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharma's 13 innovative drug projects including HY-0007; Pacific Securities said Hongbo Medical's commercial production is accelerating after the patent expiry of ticagrelor; and Southwest Securities stated CanSino's overseas clinical trials are accelerating, potentially unlocking mid-to-long-term pipeline value.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
Chinese A-share markets rose across the board at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic consultations, covering bilateral trade, investment, and AI issues. The National Medical Products Administration and General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports, effective immediately. Sector-wise, recombinant protein, CRO, biopharmaceuticals, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Biotech's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharmaceutical's 13 innovative drug projects including HY-0007; Pacific Securities predicted rapid growth for Hongbo Medical after patent expiry for ticagrelor; and Southwest Securities said CanSino's overseas clinical acceleration could unlock long-term pipeline value.
Read sourceChina A-Share Innovation Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
Chinese A-share markets rose across the board at midday on September 20, 2025, with the Shanghai Composite Index up 0.55% to 3,933.37, the Shenzhen Component up 0.57%, and the ChiNext Index up 0.93%. The People's Bank of China conducted a 165 billion yuan 7-day reverse repo operation at a rate of 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with U.S. Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on artificial intelligence. The National Medical Products Administration and the General Administration of Customs announced a pilot program for electronic customs clearance of imported pharmaceuticals at Beijing ports. Sector-wise, recombinant proteins, CRO, biologics, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts from Tianfeng Securities, Southwest Securities, and Pacific Securities provided positive outlooks on specific companies: Chengdu Firstar's HAILO platform and RIPTAC projects, Huiyu Pharmaceutical's HY-0007 dual-antibody fusion protein in Phase I trials, Hongbo Medical's commercialization ramp after patent expiry, and CanSino's accelerated overseas clinical trials.
Read sourceChina A-Share Biotech Stocks Surge; Shanghai Composite Rises 0.55% at Midday
China's A-share markets rose across the board at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at a 1.40% rate. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on artificial intelligence. The National Medical Products Administration and the General Administration of Customs announced a pilot program for electronic customs clearance of imported drugs at Beijing ports, effective immediately. Sector-wise, recombinant protein, CRO, biotech, chemical pharma, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts from Tianfeng, Southwest, Pacific, and other securities firms issued positive forecasts for specific biotech companies: Tianfeng noted Chengdu First's HAILO platform progress; Southwest highlighted Huiyu Pharma's HY-0007 dual antibody fusion protein trial; Pacific cited Hongbo Medical's commercial production ramp-up after patent expiry; and Southwest noted CanSino's overseas clinical acceleration.
Read source